Fiche société
Pfizer
Traitements, essais et publications liés.
Traitements45programmes
Essais34liés
Publications20liées
SourceDBlocale
Traitements
45| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| ALLR3This prospective, randomized, multicenter, open-label Phase 2 study is designed to evaluate the superiority of InO monotherapy vs ALLR3 after 1 cycle of induction treatment in paediatric participants (between 1 and \<18 years) with High Risk (HR) or very high risk (VHR) first bone marrow relapse CD22-positive BCP ALL, and to evaluate the safety and tolerability, PK and long-term efficacy. Treatment with study intervention will end after induction therapy; follow-up will continue for up to 5 years from randomization. | Cancer | Phase 2 | À vérifier | Austria, Belgium, Czechia, Denmark, Finland, France, Germany, Israel, … | À vérifier |
| BinimetinibThe purpose of this study is to learn about the effects of three study medicines (encorafenib, binimetinib, and pembrolizumab) given together for the treatment of melanoma that: * is advanced or metastatic (spread to other parts of the body); * has a certain type of abnormal gene called "BRAF"; and * has not received prior treatment. All participants in this study will receive pembrolizumab at the study clinic once every 3 weeks as an intravenous (IV) infusion (given directly into a vein). In addition, half of the participants will take encorafenib and binimetinib orally (by mouth) at home every day. Participants may receive pembrolizumab for up to two years. Those participants taking encorafenib and binimetinib can continue until their melanoma is no longer responding. The study team will monitor how each participant is doing with the study treatment during regular visits at the study clinic. | Cancer | Phase 3 | À vérifier | United States, Argentina, Austria, Belgium, Brazil, Bulgaria, Canada, Czechia, … | À vérifier |
| bortezomibThis phase II trial is studying how well giving bortezomib together with liposomal doxorubicin hydrochloride, dexamethasone, and cyclophosphamide works in treating patients with multiple myeloma that relapsed after autologous stem cell transplant. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as liposomal doxorubicin hydrochloride, dexamethasone, and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving bortezomib together with liposomal doxorubicin hydrochloride, dexamethasone, and cyclophosphamide may kill more cancer cells. | Cancer | Phase 3 | Thérapie cellulaire | United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, Croatia, … | À vérifier |
| ChemotherapyThis phase III trial compares standard of care hormone therapy plus ribociclib to chemotherapy followed by hormone therapy plus ribociclib for the treatment of patients with high anatomic stage breast cancer with low risk of the cancer returning (low risk recurrence). Ribociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hormone therapy, with letrozole, anastrozole or exemestane, lowers the amount of estrogen made by the body. This may help stop the growth of tumor cells that need estrogen to grow. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Hormone therapy plus ribociclib may work as well as chemotherapy followed by hormone therapy plus ribociclib for the treatment of high anatomic stage breast cancer with low recurrence risk. | Cancer | Phase 2 | Ablation tumorale non thermique | United States, Australia, Brazil, China, France, Hong Kong, India, Israel, … | Dispositif/procédure : résultats à interpréter par essai et indication. |
| CONFIDENCE — A Real-world, Prospective Observational Study of Rimegepant ODT for the Acute Treatment of Migraine Attacks in Adults.This study aims at characterizing the effectiveness of rimegepant as an acute migraine treatment in a real world setting on two aspects: * Consistency of response to rimegepant across multiple attacks * Effectiveness of rimegepant in users taking concomitant migraine preventive medications, namely monoclonal antibodies targeting CGRP and onabotulinumtoxinA | Migraine | À vérifier | À vérifier | United States | À vérifier |
| ElotuzumabThe purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). This study is seeking participants who: * Are 18 years of age or older and have MM. * Have received treatments before for MM. * Have MM that has returned or not responded to their most recent treatment. Half of the participants will receive elranatamab. The other half of participants will receive a combination therapy selected by the study doctor. The selected combination therapy will include 2 to 3 different medicines commonly used to treat MM. Elranatamab will be given as a shot under the skin at the study clinic about once a week. This may change to a smaller number of shots later in the study. The medicines in the combination therapy will be taken by mouth (at home or at the study clinic) AND will be given either as: * a shot under the skin at the study clinic * through a needle in the vein at the study clinic The number of times these medicines will be taken depends on what combination therapy the study doctor selects. Participants may continue to receive elranatamab or a combination therapy until their MM is no longer responding. The study team will see how each participant is doing with the study treatment during regular visits at the study clinic. The study team will continue to follow-up with participants after study treatment with telephone contacts (or visits). The study will compare the experiences of people receiving elranatamab to those people receiving a combination therapy. This will help learn about the safety and how effective elranatamab is. | Cancer | Phase 3 | À vérifier | United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, Croatia, … | À vérifier |
| ElranatamabThe purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). This study is seeking participants who: * Are 18 years of age or older and have MM. * Have received treatments before for MM. * Have MM that has returned or not responded to their most recent treatment. Half of the participants will receive elranatamab. The other half of participants will receive a combination therapy selected by the study doctor. The selected combination therapy will include 2 to 3 different medicines commonly used to treat MM. Elranatamab will be given as a shot under the skin at the study clinic about once a week. This may change to a smaller number of shots later in the study. The medicines in the combination therapy will be taken by mouth (at home or at the study clinic) AND will be given either as: * a shot under the skin at the study clinic * through a needle in the vein at the study clinic The number of times these medicines will be taken depends on what combination therapy the study doctor selects. Participants may continue to receive elranatamab or a combination therapy until their MM is no longer responding. The study team will see how each participant is doing with the study treatment during regular visits at the study clinic. The study team will continue to follow-up with participants after study treatment with telephone contacts (or visits). The study will compare the experiences of people receiving elranatamab to those people receiving a combination therapy. This will help learn about the safety and how effective elranatamab is. | Cancer | Phase 3 | À vérifier | United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, Croatia, … | À vérifier |
| High Dose PF-07328948The purpose of this study is to learn about the safety and effects of the study medicine (PF-07328948) for the possible treatment of heart failure (HF). | Insuffisance cardiaque | Phase 2 | À vérifier | United States, Argentina, Brazil, Bulgaria, Canada, China, Czechia, France, … | À vérifier |
| Inotuzumab ozogamicinThis prospective, randomized, multicenter, open-label Phase 2 study is designed to evaluate the superiority of InO monotherapy vs ALLR3 after 1 cycle of induction treatment in paediatric participants (between 1 and \<18 years) with High Risk (HR) or very high risk (VHR) first bone marrow relapse CD22-positive BCP ALL, and to evaluate the safety and tolerability, PK and long-term efficacy. Treatment with study intervention will end after induction therapy; follow-up will continue for up to 5 years from randomization. | Cancer | Phase 2 | À vérifier | Austria, Belgium, Czechia, Denmark, Finland, France, Germany, Israel, … | À vérifier |
| Low Dose PF-07328948The purpose of this study is to learn about the safety and effects of the study medicine (PF-07328948) for the possible treatment of heart failure (HF). | Insuffisance cardiaque | Phase 2 | À vérifier | United States, Argentina, Brazil, Bulgaria, Canada, China, Czechia, France, … | À vérifier |
| Medium Dose PF-07328948The purpose of this study is to learn about the safety and effects of the study medicine (PF-07328948) for the possible treatment of heart failure (HF). | Insuffisance cardiaque | Phase 2 | À vérifier | United States, Argentina, Brazil, Bulgaria, Canada, China, Czechia, France, … | À vérifier |
| ODT Reference formulationThe purpose of this study is to assess the bioequivalence of an alternative ODT formulation (ODT2) versus the approved ODT formulation of a CGRP receptor antagonist in healthy adult participants under fasting conditions. | Migraine | Phase 1 | À vérifier | Belgium | À vérifier |
| ODT2 Test formulationThe purpose of this study is to assess the bioequivalence of an alternative ODT formulation (ODT2) versus the approved ODT formulation of a CGRP receptor antagonist in healthy adult participants under fasting conditions. | Migraine | Phase 1 | À vérifier | Belgium | À vérifier |
| PF-06821497This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve. | Cancer | Phase 3 | À vérifier | United States, Argentina, Brazil, Bulgaria, Canada, Chile, China, Czechia, … | À vérifier |
| PF-06823859The purpose of this study is to learn about the effects, safety and how PF-06823859 is processed in adults with cutaneous lupus erythematosus (CLE) or systemic lupus erythematosus (SLE) showing some skin symptoms. This study is seeking for participants who: * are adults of 18 years of age or older. * are confirmed to have CLE or SLE with involvement of the skin. * have a Cutaneous Lupus Erythematosus Disease Area and Severity Index activity (CLASI-A) score of at least 8. About 48 participants will be selected to receive active study medicine (PF-06823859) or placebo (an infusion without drug). About 32 are grouped to receive the active study medicine and 16 are to receive placebo. They will be receiving the treatments by intravenous infusion (injected directly into the veins). At week 16 all participants receiving the active study drug since day 1 and participants who have received placebo since day 1 and are not responding clinically will receive active study medication. Patients who have received placebo since Day 1 and who have had a clinical response will continue to receive placebo till week 40. All participants will have last follow-up visit at Week 60. The study will compare participants receiving PF-06823859 to participants who receive placebo. This will help us see if PF-06823859 is safe and effective to treat CLE or SLE with skin symptoms and improve participant's CLASI-A score. Participants will take part in this study for about 65 weeks. This includes up to a 5-week selection period, a 12-week Q4Wk treatment period, a 36-week Q8Wk treatment period, and a 12-week follow-up period. | Lupus | Phase 2 | Traitement symptomatique | United States, Canada, Greece, Spain | À vérifier |
| PF-06939926The study will evaluate the safety and efficacy of gene therapy in boys with DMD. It is a randomized, double-blind, placebo-controlled study with two thirds of participants assigned to gene therapy. The one third of participants who are randomized to the placebo arm will have an opportunity for treatment with gene therapy at the beginning of the second year. | Myopathies | Phase 3 | Thérapie génique | United States, Australia, Belgium, Canada, France, Germany, Israel, Italy, … | À vérifier |
| PF-07799544The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) alone or in combination as a potential cancer treatment for adults with advanced solid tumors. The study will be conducted in two parts: PF-07799544 as a single agent (Phase 1a) and PF-07799544 in combination with another study medicine called PF-07799933 (Phase 1b). Phase 1a is no longer open for enrollment. In Phase1b (noted as "this study"), we are seeking participants who have: * a solid tumor which is metastatic or recurrent (excluding colorectal cancer) * tumor with the mutation (abnormal gene) called "BRAF V600" * received required prior treatment for cancer per cohort assigned. All participants in this study will receive both study medicines. Both study medicines are tablets that are taken by mouth at home twice a day. Participants will receive study medicines until their cancer is no longer responding, unacceptable side effects, or 2 years. Participants may continue to receive study therapy beyond 2 years. We will examine the experiences of people receiving the study medicines. This will help us determine if the study medicines are safe and effective. | Cancer | Phase 1 | À vérifier | United States, Australia, Brazil, Canada, China, Israel, Japan | À vérifier |
| PF-07799933The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) alone or in combination as a potential cancer treatment for adults with advanced solid tumors. The study will be conducted in two parts: PF-07799544 as a single agent (Phase 1a) and PF-07799544 in combination with another study medicine called PF-07799933 (Phase 1b). Phase 1a is no longer open for enrollment. In Phase1b (noted as "this study"), we are seeking participants who have: * a solid tumor which is metastatic or recurrent (excluding colorectal cancer) * tumor with the mutation (abnormal gene) called "BRAF V600" * received required prior treatment for cancer per cohort assigned. All participants in this study will receive both study medicines. Both study medicines are tablets that are taken by mouth at home twice a day. Participants will receive study medicines until their cancer is no longer responding, unacceptable side effects, or 2 years. Participants may continue to receive study therapy beyond 2 years. We will examine the experiences of people receiving the study medicines. This will help us determine if the study medicines are safe and effective. | Cancer | Phase 1 | À vérifier | United States, Australia, Brazil, Canada, China, Israel, Japan | À vérifier |
| PF-08154225The purpose of this study is to learn about the safety and effects of the study medication called PF-08154225 for the potential treatment of autoimmune diseases. An autoimmune disease is a condition that makes a person's immune system attack its healthy cells by mistake. This study is particularly looking at autoimmune diseases called as Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myositis (IIM) or Systemic Sclerosis (SSc). This study is divided into 3 parts: Part 1a, Part 1b and Part 2. Parts 1a and 1b are seeking participants with Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis and Part 2 with also Idiopathic Inflammatory Myositis (IIM) or Systemic Sclerosis (SSc). Participants can take part only in one part of the study. All participants in this study will receive PF-08154225 at the study clinic. In Part 1a participants will receive single administration of PF-08154225 after which they will be observed at the study clinic during regular visits through week 16 or longer. In Part 1b the participants will receive multiple administration of PF-08154225 after which they will be monitored in similar a manner as in Part 1a through week 24 or longer. In Part 2 participants will receive multiple administrations of PF-08154225. After the last injection they will be monitored for safety through week 52 or longer. | Lupus, Myopathies | Phase 1/2 | Immunomodulation | À vérifier | |
| PF-08161842The purpose of this clinical study is to learn about the safety and effects of the study medicine (called PF-08161842) and how it is processed by the body. This is the first time PF-08161842 will be given to people. This study is seeking healthy adults: * 18 to 64 years of age or 65 to 85 years of age * Who are in generally good health * Who meet study conditions for body weight and body mass index (BMI) Participants will receive either PF-08161842 tablets or matching placebo tablets. Placebo tablets do not contain active medicine. In some study groups, participants will receive a single dose of study medicine. In other study groups, they will receive the study medicine for 14 days. The tablets will be taken by mouth at the study clinic. The investigators will compare the experiences of people receiving the study medicine with those of people who do not. This will help researchers determine if PF-08161842 is safe and how it affects the body. Participants will stay at the study clinic for several days so the study team can closely monitor their health. The study will include physical examinations, checks of blood pressure, heart rate, temperature, and breathing. It will also include blood and urine samples and heart tracing tests (ECGs). Researchers will assess how the body processes the study medicine. Some participants will also have lumbar punctures (spinal taps) to collect small samples of fluid from around the brain and spinal cord. The study team will monitor participants for any reactions throughout the study. For people receiving a single dose, the study will last for about 9 weeks. For those receiving multiple doses the study will last for about 11 weeks. This includes screening, study visits, clinic stay, and follow-up contact after the last dose. | Alzheimer | Phase 1 | À vérifier | À vérifier | |
| PF-08634404This study is being done to learn more about a new medicine called PF-08634404. The study team wants to understand how well PF-08634404 works when given alone or with chemotherapy . Chemotherapy is a type of cancer treatment that uses medicines to destroy cancer cells or stop them from growing. The study is for adults with Transformed Small Cell Lung Cancer (T-SCLC ). T SCLC is a rare lung cancer that happens when one type of lung cancer changes into a more aggressive type after treatment stops working. To join the study, participants must meet the following conditions: * Are aged 18 years or older * Diagnosed with T-SCLC and have not received treatment for this type of lung cancer (a single cycle of chemotherapy may be permitted) * Prior diagnosis of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer treated with tyrosine kinase inhibitors (TKIs) * Have healthy organs based on medical tests and are in good physical condition After joining the study, adults will be given chemotherapy in addition to the study medicine. After this combination treatment is finished, the study medicine will be continued alone. Adults will receive the treatment through IV infusions (medicine given directly into a vein). All treatments will be done at clinical study sites, where a trained medical team will monitor adults during and after each visit. | Cancer | Phase 2 | À vérifier | United States, Australia, Brazil, China, France, Hong Kong, India, Israel, … | À vérifier |
| Rimegepant (PF-07899801)The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of migraine in children and adolescents (≥ 6 to \< 18 years of age). | Migraine | Phase 3 | À vérifier | United States, Poland, Spain | À vérifier |
| Rimegepant 75mg daily dosingThe purpose of this study is to compare the efficacy and safety of daily and every other day dosing of rimegepant to placebo as a preventive treatment for episodic migraine. | Migraine | Phase 4 | À vérifier | United States, Austria, Canada, France, Germany, Italy, Poland, Spain, … | À vérifier |
| Rimegepant 75mg every other day dosingThe purpose of this study is to compare the efficacy and safety of daily and every other day dosing of rimegepant to placebo as a preventive treatment for episodic migraine. | Migraine | Phase 4 | À vérifier | United States, Austria, Canada, France, Germany, Italy, Poland, Spain, … | À vérifier |
| Rimegepant for acute migraine treatmentThis is a non-interventional, prospective study that will enroll participants with migraine in the United Kingdom currently in use of rimegepant to acutely treat migraine attacks. Participants will be followed up for up to 12 weeks and will complete a daily questionnaire to self-report the consistency of response to rimegepant in acute treatment of migraine. | Migraine | À vérifier | À vérifier | United Kingdom | À vérifier |
| Rimegepant sulfateThe purpose of this study is to evaluate safety and effectiveness of NURTEC® ODT 75 mg (Rimegepant sulfate) in adult patients with acute treatment of migraine with or without aura and with preventive treatment of episodic migraine during the PMS period as required by the Korean ministry of food and drug safety (MFDS). | Migraine | À vérifier | À vérifier | À vérifier | |
| Rimegepant/BHV3000The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in children and adolescents. | Migraine | Phase 3 | À vérifier | United States, Canada, China, Japan, Mexico, Poland, Spain, Sweden, … | À vérifier |
| VariousThe purpose of the study is to evaluate the risk of pregnancy and infant outcomes among women with migraine exposed to rimegepant during pregnancy and in two rimegepant unexposed comparator groups. | Migraine | À vérifier | À vérifier | United States | À vérifier |
| Rimegepant/BHV3000The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in children and adolescents. | Migraine | Phase 3 | À vérifier | United States, Canada, China, Japan, Mexico, Poland, Spain, Sweden, United Kingdom | À vérifier |
| Rimegepant (PF-07899801)The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of migraine in children and adolescents (≥ 6 to \< 18 years of age). | Migraine | Phase 3 | À vérifier | United States, Poland, Spain | À vérifier |
| Rimegepant 75mg daily dosingThe purpose of this study is to compare the efficacy and safety of daily and every other day dosing of rimegepant to placebo as a preventive treatment for episodic migraine. | Migraine | Phase 4 | À vérifier | United States, Austria, Canada, France, Germany, Italy, Poland, Spain, Sweden, United Kingdom | À vérifier |
| Rimegepant sulfateThe purpose of this study is to evaluate safety and effectiveness of NURTEC® ODT 75 mg (Rimegepant sulfate) in adult patients with acute treatment of migraine with or without aura and with preventive treatment of episodic migraine during the PMS period as required by the Korean ministry of food and drug safety (MFDS). | Migraine | À vérifier | À vérifier | À vérifier | |
| PF-06823859The purpose of this study is to learn about the effects, safety and how PF-06823859 is processed in adults with cutaneous lupus erythematosus (CLE) or systemic lupus erythematosus (SLE) showing some skin symptoms. This study is seeking for participants who: * are adults of 18 years of age or older. * are confirmed to have CLE or SLE with involvement of the skin. * have a Cutaneous Lupus Erythematosus Disease Area and Severity Index activity (CLASI-A) score of at least 8. About 48 participants will be selected to receive active study medicine (PF-06823859) or placebo (an infusion without drug). About 32 are grouped to receive the active study medicine and 16 are to receive placebo. They will be receiving the treatments by intravenous infusion (injected directly into the veins). At week 16 all participants receiving the active study drug since day 1 and participants who have received placebo since day 1 and are not responding clinically will receive active study medication. Patients who have received placebo since Day 1 and who have had a clinical response will continue to receive placebo till week 40. All participants will have last follow-up visit at Week 60. The study will compare participants receiving PF-06823859 to participants who receive placebo. This will help us see if PF-06823859 is safe and effective to treat CLE or SLE with skin symptoms and improve participant's CLASI-A score. Participants will take part in this study for about 65 weeks. This includes up to a 5-week selection period, a 12-week Q4Wk treatment period, a 36-week Q8Wk treatment period, and a 12-week follow-up period. | Lupus | Phase 2 | Traitement symptomatique | United States, Canada, Greece, Spain | À vérifier |
| PF-06939926The study will evaluate the safety and efficacy of gene therapy in boys with DMD. It is a randomized, double-blind, placebo-controlled study with two thirds of participants assigned to gene therapy. The one third of participants who are randomized to the placebo arm will have an opportunity for treatment with gene therapy at the beginning of the second year. | Myopathies | Phase 3 | Thérapie génique | United States, Australia, Belgium, Canada, France, Germany, Israel, Italy, Japan, Russia, South Korea, Spain, Switzerland, Taiwan, United Kingdom | À vérifier |
| CONFIDENCE — A Real-world, Prospective Observational Study of Rimegepant ODT for the Acute Treatment of Migraine Attacks in Adults.This study aims at characterizing the effectiveness of rimegepant as an acute migraine treatment in a real world setting on two aspects: * Consistency of response to rimegepant across multiple attacks * Effectiveness of rimegepant in users taking concomitant migraine preventive medications, namely monoclonal antibodies targeting CGRP and onabotulinumtoxinA | Migraine | À vérifier | À vérifier | United States | À vérifier |
| PF-07799544The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) alone or in combination as a potential cancer treatment for adults with advanced solid tumors. The study will be conducted in two parts: PF-07799544 as a single agent (Phase 1a) and PF-07799544 in combination with another study medicine called PF-07799933 (Phase 1b). Phase 1a is no longer open for enrollment. In Phase1b (noted as "this study"), we are seeking participants who have: * a solid tumor which is metastatic or recurrent (excluding colorectal cancer) * tumor with the mutation (abnormal gene) called "BRAF V600" * received required prior treatment for cancer per cohort assigned. All participants in this study will receive both study medicines. Both study medicines are tablets that are taken by mouth at home twice a day. Participants will receive study medicines until their cancer is no longer responding, unacceptable side effects, or 2 years. Participants may continue to receive study therapy beyond 2 years. We will examine the experiences of people receiving the study medicines. This will help us determine if the study medicines are safe and effective. | Cancer | Phase 1 | À vérifier | United States, Australia, Brazil, Canada, China, Israel, Japan | À vérifier |
| Inotuzumab ozogamicinThis prospective, randomized, multicenter, open-label Phase 2 study is designed to evaluate the superiority of InO monotherapy vs ALLR3 after 1 cycle of induction treatment in paediatric participants (between 1 and \<18 years) with High Risk (HR) or very high risk (VHR) first bone marrow relapse CD22-positive BCP ALL, and to evaluate the safety and tolerability, PK and long-term efficacy. Treatment with study intervention will end after induction therapy; follow-up will continue for up to 5 years from randomization. | Cancer | Phase 2 | À vérifier | Austria, Belgium, Czechia, Denmark, Finland, France, Germany, Israel, Italy, Netherlands, Norway, Poland, Slovakia, Spain, Sweden, Switzerland | À vérifier |
| ElranatamabThe purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). This study is seeking participants who: * Are 18 years of age or older and have MM. * Have received treatments before for MM. * Have MM that has returned or not responded to their most recent treatment. Half of the participants will receive elranatamab. The other half of participants will receive a combination therapy selected by the study doctor. The selected combination therapy will include 2 to 3 different medicines commonly used to treat MM. Elranatamab will be given as a shot under the skin at the study clinic about once a week. This may change to a smaller number of shots later in the study. The medicines in the combination therapy will be taken by mouth (at home or at the study clinic) AND will be given either as: * a shot under the skin at the study clinic * through a needle in the vein at the study clinic The number of times these medicines will be taken depends on what combination therapy the study doctor selects. Participants may continue to receive elranatamab or a combination therapy until their MM is no longer responding. The study team will see how each participant is doing with the study treatment during regular visits at the study clinic. The study team will continue to follow-up with participants after study treatment with telephone contacts (or visits). The study will compare the experiences of people receiving elranatamab to those people receiving a combination therapy. This will help learn about the safety and how effective elranatamab is. | Cancer | Phase 3 | À vérifier | United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, Croatia, Czechia, Denmark, Finland, France, Germany, Greece, Israel, Italy, Japan, Netherlands, Norway, Portugal, … | À vérifier |
| PF-06821497This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve. | Cancer | Phase 3 | À vérifier | United States, Argentina, Brazil, Bulgaria, Canada, Chile, China, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, Italy, Japan, Netherlands, New Zealand, Poland, Slovakia, … | À vérifier |
| PF-08154225The purpose of this study is to learn about the safety and effects of the study medication called PF-08154225 for the potential treatment of autoimmune diseases. An autoimmune disease is a condition that makes a person's immune system attack its healthy cells by mistake. This study is particularly looking at autoimmune diseases called as Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myositis (IIM) or Systemic Sclerosis (SSc). This study is divided into 3 parts: Part 1a, Part 1b and Part 2. Parts 1a and 1b are seeking participants with Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis and Part 2 with also Idiopathic Inflammatory Myositis (IIM) or Systemic Sclerosis (SSc). Participants can take part only in one part of the study. All participants in this study will receive PF-08154225 at the study clinic. In Part 1a participants will receive single administration of PF-08154225 after which they will be observed at the study clinic during regular visits through week 16 or longer. In Part 1b the participants will receive multiple administration of PF-08154225 after which they will be monitored in similar a manner as in Part 1a through week 24 or longer. In Part 2 participants will receive multiple administrations of PF-08154225. After the last injection they will be monitored for safety through week 52 or longer. | Myopathies | Phase 1/2 | Immunomodulation | À vérifier | |
| ODT2 Test formulationThe purpose of this study is to assess the bioequivalence of an alternative ODT formulation (ODT2) versus the approved ODT formulation of a CGRP receptor antagonist in healthy adult participants under fasting conditions. | Migraine | Phase 1 | À vérifier | Belgium | À vérifier |
| PF-08634404This study is being done to learn more about a new medicine called PF-08634404. The study team wants to understand how well PF-08634404 works when given alone or with chemotherapy . Chemotherapy is a type of cancer treatment that uses medicines to destroy cancer cells or stop them from growing. The study is for adults with Transformed Small Cell Lung Cancer (T-SCLC ). T SCLC is a rare lung cancer that happens when one type of lung cancer changes into a more aggressive type after treatment stops working. To join the study, participants must meet the following conditions: * Are aged 18 years or older * Diagnosed with T-SCLC and have not received treatment for this type of lung cancer (a single cycle of chemotherapy may be permitted) * Prior diagnosis of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer treated with tyrosine kinase inhibitors (TKIs) * Have healthy organs based on medical tests and are in good physical condition After joining the study, adults will be given chemotherapy in addition to the study medicine. After this combination treatment is finished, the study medicine will be continued alone. Adults will receive the treatment through IV infusions (medicine given directly into a vein). All treatments will be done at clinical study sites, where a trained medical team will monitor adults during and after each visit. | Cancer | Phase 2 | À vérifier | United States, Australia, Brazil, China, France, Hong Kong, India, Israel, Italy, Japan, Spain, Taiwan | À vérifier |
| Low Dose PF-07328948The purpose of this study is to learn about the safety and effects of the study medicine (PF-07328948) for the possible treatment of heart failure (HF). | Insuffisance cardiaque | Phase 2 | À vérifier | United States, Argentina, Brazil, Bulgaria, Canada, China, Czechia, France, Hungary, Japan, Poland, Puerto Rico, Spain, United Kingdom | À vérifier |
| PF-08161842The purpose of this clinical study is to learn about the safety and effects of the study medicine (called PF-08161842) and how it is processed by the body. This is the first time PF-08161842 will be given to people. This study is seeking healthy adults: * 18 to 64 years of age or 65 to 85 years of age * Who are in generally good health * Who meet study conditions for body weight and body mass index (BMI) Participants will receive either PF-08161842 tablets or matching placebo tablets. Placebo tablets do not contain active medicine. In some study groups, participants will receive a single dose of study medicine. In other study groups, they will receive the study medicine for 14 days. The tablets will be taken by mouth at the study clinic. The investigators will compare the experiences of people receiving the study medicine with those of people who do not. This will help researchers determine if PF-08161842 is safe and how it affects the body. Participants will stay at the study clinic for several days so the study team can closely monitor their health. The study will include physical examinations, checks of blood pressure, heart rate, temperature, and breathing. It will also include blood and urine samples and heart tracing tests (ECGs). Researchers will assess how the body processes the study medicine. Some participants will also have lumbar punctures (spinal taps) to collect small samples of fluid from around the brain and spinal cord. The study team will monitor participants for any reactions throughout the study. For people receiving a single dose, the study will last for about 9 weeks. For those receiving multiple doses the study will last for about 11 weeks. This includes screening, study visits, clinic stay, and follow-up contact after the last dose. | Alzheimer | Phase 1 | À vérifier | À vérifier | |
| Rimegepant for acute migraine treatmentThis is a non-interventional, prospective study that will enroll participants with migraine in the United Kingdom currently in use of rimegepant to acutely treat migraine attacks. Participants will be followed up for up to 12 weeks and will complete a daily questionnaire to self-report the consistency of response to rimegepant in acute treatment of migraine. | Migraine | À vérifier | À vérifier | United Kingdom | À vérifier |
Essais cliniques
34| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Rimegepant for acute migraine treatment | Migraine | À vérifier | NCT06898047 | CORRELATE-UK — Consistency of Response With Rimegepant in Acute Treatment of Migraine | ACTIVE_NOT_RECRUITING |
| Rimegepant | Migraine | À vérifier | NCT07906262 | Efficacy of Rimegepant 75 mg for the Acute Treatment of Migraine: a Bayesian Individual Participant Data Meta-analysis Standardized to Defined Target Populations | ACTIVE_NOT_RECRUITING |
| PF-08161842 | Alzheimer | Phase 1 | NCT07897708 | A Study to Learn How Different Amounts of the Study Medicine Called PF-08161842 Are Tolerated and Act in the Body in Healthy and Older Adults | NOT_YET_RECRUITING |
| Low Dose PF-07328948 | Insuffisance cardiaque | Phase 2 | NCT06991257 | A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF) | RECRUITING |
| PF-08634404 | Cancer | Phase 2 | NCT07476287 | Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer | RECRUITING |
| Zavegepant | Migraine | Phase 1 | NCT06995729 | A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine | RECRUITING |
| ODT2 Test formulation | Migraine | Phase 1 | NCT07594769 | A Study to Compare the Blood Levels of Two Dosage Formulations of the Study Medicine in Healthy Adults | COMPLETED |
| Encorafenib | Cancer | Phase 3 | NCT04657991 | A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma | ACTIVE_NOT_RECRUITING |
| Rimegepant | Migraine | Phase 3 | NCT05810038 | A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects. | COMPLETED |
| PF-08154225 | Myopathies | Phase 1/2 | NCT07782450 | A Study to Learn About a Medicine Called PF-08154225 in Participants With Autoimmune Diseases | NOT_YET_RECRUITING |
| Rimegepant | Migraine | À vérifier | NCT05198245 | Study of Pregnancy Outcomes in Women Exposed to Rimegepant During Pregnancy | ACTIVE_NOT_RECRUITING |
| PF-06821497 | Cancer | Phase 3 | NCT06629779 | A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. | RECRUITING |
| Elranatamab | Cancer | Phase 3 | NCT06152575 | MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) | RECRUITING |
| Inotuzumab ozogamicin | Cancer | Phase 2 | NCT05748171 | A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL | RECRUITING |
| PF-07799544 | Cancer | Phase 1 | NCT05538130 | A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors | RECRUITING |
| Rimegepant | Migraine | Phase 3 | NCT03235479 | Safety and Efficacy Study in Adult Subjects With Acute Migraines | COMPLETED |
| Rimegepant | Migraine | Phase 3 | NCT03237845 | Safety and Efficacy in Adult Subjects With Acute Migraines | COMPLETED |
| CONFIDENCE — A Real-world, Prospective Observational Study of Rimegepant ODT for the Acute Treatment of Migraine Attacks in Adults. | Migraine | À vérifier | NCT06467370 | CONFIDENCE — A Real-world, Prospective Observational Study of Rimegepant ODT for the Acute Treatment of Migraine Attacks in Adults. | COMPLETED |
| Rimegepant | Migraine | Phase 3 | NCT03461757 | Trial in Adult Subjects With Acute Migraines | COMPLETED |
| Rimegepant 75 mg ODT | Migraine | Phase 4 | NCT07685769 | A Study to Find Out if the Medicine Called Rimegepant is Safe for Adults in India | RECRUITING |
| Rimegepant | Migraine | Phase 3 | NCT06641466 | A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine | RECRUITING |
| PF-06939926 | Myopathies | Phase 3 | NCT04281485 | Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy | ACTIVE_NOT_RECRUITING |
| PF-06823859 | Lupus | Phase 2 | NCT05879718 | A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms. | TERMINATED |
| Rimegepant sulfate | Migraine | À vérifier | NCT07497854 | Rimegepant PMS — A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea | NOT_YET_RECRUITING |
| Rimegepant | Migraine | Phase 4 | NCT05207865 | Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention | COMPLETED |
| Rimegepant 75mg daily dosing | Migraine | Phase 4 | NCT05217927 | Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens | COMPLETED |
| Rimegepant | Migraine | Phase 3 | NCT07729462 | A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine | RECRUITING |
| Rimegepant | Migraine | Phase 3 | NCT05156398 | Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects | RECRUITING |
| Rimegepant | Migraine | Phase 4 | NCT07609914 | A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine | RECRUITING |
| Rimegepant | Migraine | Phase 3 | NCT06616194 | A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine | ACTIVE_NOT_RECRUITING |
| Rimegepant (PF-07899801) | Migraine | Phase 3 | NCT04743141 | Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine | RECRUITING |
| Rimegepant/BHV3000 | Migraine | Phase 3 | NCT04649242 | Randomized Study in Children and Adolescents With Migraine: Acute Treatment | RECRUITING |
| Rimegepant | Migraine | Phase 2/3 | NCT03266588 | Open Label Safety Study in Acute Treatment of Migraine | COMPLETED |
| pregabalin | Épilepsie | Phase 3 | NCT00141388 | To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures | COMPLETED |
Publications
20| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| ODT Reference formulation | Bioequivalence of Aripiprazole Oral Soluble Films and Orally Disintegrating Tablets in Healthy Participants: A Crossover Study. | Clinical and translational science | ||
| ODT Reference formulation | Agree to disagree: Increasing the impact of recommendations formulated through Delphi methodology. | Journal of hepatology | ||
| ODT Reference formulation | Pharmacokinetic and Bioequivalence of Mirtazapine Orally Disintegrating Tablets: A Randomized, Crossover Study. | Clinical pharmacology in drug development | ||
| Rimegepant sulfate | Early Experience Treating Vestibular Migraine With Small Molecule CGRP Antagonists. | Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery | ||
| Rimegepant sulfate | Rimegepant for migraine prevention in clinical practice: A multicenter study including patients with prior anti-CGRP monoclonal antibody failure (GEMA project). | Cephalalgia : an international journal of headache | ||
| Rimegepant 75mg daily dosing | A Phase 1, Randomized, Placebo-Controlled, Multiple-Dose, Double-Blind Study to Evaluate and Compare the Pharmacokinetics and Safety of Rimegepant in Healthy Adult Japanese and Caucasian Individuals. | Clinical pharmacology in drug development | ||
| Rimegepant/BHV3000 | Comparative efficacy, quality of life, safety, and tolerability of atogepant and rimegepant in migraine prevention: A matching-adjusted indirect comparison analysis. | Cephalalgia : an international journal of headache | ||
| Rimegepant/BHV3000 | Cost per treatment responder analysis of atogepant compared to rimegepant for the preventive treatment of episodic migraine. | Headache | ||
| Chemotherapy | Transpapillary Placement of a Multihole Covered Metal Stent Using a 5.9-Fr Delivery System Through a Forward-viewing Endoscope in Malignant Biliary Obstruction With Type I Duodenal Stenosis. | DEN open | ||
| bortezomib | Proliferative glomerulonephritis with monoclonal IgG3 deposits: A case series. | Journal of translational autoimmunity | ||
| bortezomib | Selinexor combined bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma with high-risk factors: a single-arm, multi-center, prospective observational clinical study. | Annals of medicine | ||
| bortezomib | A fast method for the quantification of bortezomib in serum and rat nervous tissue by liquid chromatography tandem mass spectrometry. | Journal of pharmaceutical and biomedical analysis | ||
| PF-06939926 | Cardiac safety of fordadistrogene movaparvovec gene therapy in Duchenne muscular dystrophy: Initial observations from a phase 1b trial. | Molecular therapy : the journal of the American Society of Gene Therapy | ||
| PF-06939926 | AAV microdystrophin gene replacement therapy for Duchenne muscular dystrophy: progress and prospects. | Gene therapy | ||
| PF-06823859 | Safety, Tolerability, and Pharmacokinetics of PF-06823859, an Anti-Interferon β Monoclonal Antibody: A Randomized, Phase I, Single- and Multiple-Ascending-Dose Study. | Clinical pharmacology in drug development | ||
| bortezomib | Targeting the mevalonate pathway sensitizes multiple myeloma cells to bortezomib through induction of mitochondrial metabolic disruption. | Cell communication and signaling : CCS | ||
| bortezomib | Adjusted delivery, stronger outcomes: Selinexor therapeutic adaptation and positioning in previously treated multiple myeloma. | British journal of haematology | ||
| bortezomib | Triptonide enhances DNA damage by inhibiting TRIP13‑mediated DNA repair and synergizes with bortezomib to suppress multiple myeloma. | International journal of oncology | ||
| bortezomib | Cysteine-mediated bortezomib resistance is governed by α-ketoacid availability. | bioRxiv : the preprint server for biology | ||
| bortezomib | Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myeloma. | Future oncology (London, England) |